Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19

COVID-19 and Cancer Consortium

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non–recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19.

Original languageEnglish (US)
Pages (from-to)181-193
Number of pages13
JournalBlood cancer discovery
Volume3
Issue number3
DOIs
StatePublished - May 1 2022

All Science Journal Classification (ASJC) codes

  • General Medicine

Cite this